EGFR and non-small cell lung carcinoma: Compared with treatment with EGFR-TKI alone, dual inhibition of VEGF and EGFR significantly improved the PFS of advanced EGFR-mutant NSCLC in first-line treatment (Landre et al., 2020; Peravali et al., 2020).